PharmaCyte Biotech shares surge 14.46% premarket after selling stake in Femasys boosts cash to $20M.

PharmaCyte Biotech surged 14.46% in premarket trading following two key developments: Director Jonathan Schechter’s purchase of 60,000 shares, signaling insider confidence, and the company’s successful sale of its stake in Femasys Inc. The latter is expected to boost PharmaCyte’s cash and marketable securities to $20 million from $13.3 million, validating its capital deployment strategy. Schechter’s transactions, totaling $48,232 across three days, and the strategic asset sale collectively reinforced investor optimism about the firm’s financial positioning and risk management.